Biomarker & Intervention Discovery
Sepsis
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
US DALYs1.25MWHO GHE 2021 · all ages
Global DALYs21.27MWHO GHE 2021 · worldwide
US mortality52.7K deaths/yrWHO GHE 2021
Global mortality385.4K deaths/yrWHO GHE 2021 · worldwide
NIH funding$207MFY2025 · RCDC estimate
Funding levelUnderfunded
Spontaneous remissionNot applicable — sepsis is an acute life-threatening syndrome; hospital mortality 15-25% for sepsis, 30-45% for septic…
Best-intervention remissionHour-1 Bundle (blood cultures + antibiotics + fluids + vasopressors): 30-40% mortality reduction vs delayed care…
Gap sizeLarge — compliance with Hour-1 Bundle varies enormously across hospitals; 3-6 hour bundle completion only in 50-70% of…
Primary barrierpractice/systems
Full remission profile →
Remission & chronicity
Spontaneous remission
Not applicable — sepsis is an acute life-threatening syndrome; hospital mortality 15-25% for sepsis, 30-45% for septic shock with standard care; long-term complications (post-sepsis syndrome) in 50-70% of survivors
Best-intervention remission
Hour-1 Bundle (blood cultures + antibiotics + fluids + vasopressors): 30-40% mortality reduction vs delayed care; vasopressin as vasopressor adjunct reduces vasopressor requirements; corticosteroids in septic shock: 3-5% absolute mortality reduction (ADRENAL, APROCCHSS); no truly curative intervention beyond source control
Gap size
Large — compliance with Hour-1 Bundle varies enormously across hospitals; 3-6 hour bundle completion only in 50-70% of hospitals
Primary barrier
practice/systems
Sepsis recognition delay is the primary driver of mortality; time-to-antibiotics is the single best predictor of outcome (each hour delay increases mortality 4-7%); early goal-directed therapy (EGDT) as originally described was abandoned after ProCESS/ARISE/ProMISe trials showed no benefit of specific protocol over usual care, creating confusion about what 'appropriate' standard care is
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Sepsis” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."